Decision of the EEA Joint Committee No 71/2026 of 20 March 2026 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2026/1263]

Official Journal EN of the European Union L series 2026/1263 25.6.2026 DECISION OF THE EEA JOINT COMMITTEENo 71/2026 of 20 March 2026 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2026/1263] THE EEA JOINT COMMITTEE, Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof, Whereas: (1) Commission Implementing Regulation (EU) 2024/2699 of 18 October 2024 laying down, pursuant to Regulation (EU) 2021/2282 of the European Parliament and of the Council, detailed procedural rules for the cooperation of the Member State Coordination Group on Health Technology Assessment and the Commission with the European Medicines Agency in the form of exchange of information as regards the joint clinical assessment of medicinal products and medical devices and in vitrodiagnostic medical devices and as regards the joint scientific consultation on medicinal products and medical devices(1)is to be incorporated into the EEA Agreement. (2) Annex II to the EEA Agreement should therefore be amended accordingly, HAS ADOPTED THIS DECISION: Article 1 The following point is inserted after point 23b (Commission Implementing Regulation (EU) 2025/117) of Chapter XIII of Annex II to the EEA Agreement: ‘23c. 32024 R 2699: Commission Implementing Regulation (EU) 2024/2699 of 18 October 2024 laying down, pursuant to Regulation (EU) 2021/2282 of the European Parliament and of the Council, detailed procedural rules for the cooperation of the Member State Coordination Group on Health Technology Assessment and the Commission with the European Medicines Agency in the form of exchange of information as regards the joint clinical assessment of medicinal products and medical devices and in vitro diagnostic medical devices and as regards the joint scientific consultation on medicinal products and medical devices (OJ L, 2024/2699, 21.10.2024).’ Article 2 The following point is inserted after point 17b (Commission Implementing Regulation (EU) 2025/117) of Chapter XXX of Annex II to the EEA Agreement: ‘17c. 32024 R 2699: Commission Implementing Regulation (EU) 2024/2699 of 18 October 2024 laying down, pursuant to Regulation (EU) 2021/2282 of the European Parliament and of the Council, detailed procedural rules for the cooperation of the Member State Coordination Group on Health Technology Assessment and the Commission with the European Medicines Agency in the form of exchange of information as regards the joint clinical assessment of medicinal products and medical devices and in vitro diagnostic medical devices and as regards the joint scientific consultation on medicinal products and medical devices (OJ L, 2024/2699, 21.10.2024).’ Article 3 The text of Implementing Regulation (EU) 2024/2699 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic. (1) OJ L, 2024/2699, 21.10.2024, ELI: http://data.europa.eu/eli/reg_impl/2024/2699/oj. ELI: http://data.europa.eu/eli/dec/2026/1263/oj 1/2EN OJ L, 25.6.2026 Article 4 This Decision shall enter into force on 21 March 2026, provided that all the notifications under Article 103(1) of the EEA Agreement have been made(*). Article 5 This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union. Done at Brussels, 20 March 2026. For the EEA Joint Committee The President Nicolas VON LINGEN (*) No constitutional requirements indicated. 2/2 ELI: http://data.europa.eu/eli/dec/2026/1263/oj